Pediatr. praxi. 2016;17(4):230-236 [Dermatol. praxi. 2016;10(1):10-15]

Maintenance therapy of acne

MUDr.Zuzana Nevoralová, Ph.D.
Dermatovenerologické oddělení, Nemocnice Jihlava

Acne is a polymorphic inflammatory disease of pilosebaceous glands. Manifestation of acne mostly repeats for years, that is why

it is considered a chronic disease. These days’strategy of its treatment includes an active phase followed by a maintenance one.

Maintenance therapy is defined as a regular use of appropriate therapeutic agents to ensure that acne remains in remission.

Maintenance therapy is, simply speaking, treatment of the microcomedo. The mainstay of therapy represents topical agents with

a comedolytic activity, especially retinoids. As an alternative azelaic acid can be used. Benzoyl peroxide is suitable in combination

with retinoids especially if inflammatory lesions are present. It is also necessary to provide additive treatment including first of

all suitable dermocosmetics and a healthy lifestyle without smoking.

Keywords: acne, maintenance therapy, microcomedo, retinoids,azelaic acid, benzoyl peroxide

Published: October 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nevoralová Z. Maintenance therapy of acne. Pediatr. praxi. 2016;17(4):230-236.
Download citation

References

  1. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J Eur Acad Dermatol Venereol 2001; 15(suppl 3): 43-49. Go to original source...
  2. Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000; 142: 1084-1091. Go to original source...
  3. Norris JFB, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol 1988; 118: 651-659. Go to original source...
  4. Gollnick HPM, Finlay AY, Shear N. Can we define acne as a chronic disease. If so, how and when. Am J Clin Dermatol 2008; 9: 279-284. Go to original source...
  5. Nast A, Dréno B, Bettoli V, et al. European Evidence-based (S3) Guidelines for the Treatment of Acne. J Eur Acad Dermatol Venereol 2012; 26(Suppl. 1): 1-29. Go to original source...
  6. Merrit B, Burkhardt C, Morell D. Use of Isotretinoin for Acne vulgaris. Pediatric Annals 2009; 38(6): 311-320. Go to original source... Go to PubMed...
  7. Gollnick HP, Cunliffe WJ, Berson DD, et al. Global Alliance to Improve Outcomes in Acne. Management of acne. J Am Acad Dermatol 2003; 49(1) (Suppl 1): S1-S37. Go to original source...
  8. Wolf JE. Maintenance therapy for acne vulgaris: the fine balance between efficacy, cutaneous tolerability, and adherence. Skinmed 2004; 3: 23-26. Go to original source...
  9. Graupe K, Cunliffe WJ, Gollnick HPM, et al. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996; 57: 230-235. Go to original source...
  10. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206: 54-56. Go to original source... Go to PubMed...
  11. Gollnick HPM. Current perspectives on the treatment of acne vulgaris and implications for future directions. J Eur Acad Dermatol Venereol 2001; 15(Suppl 3): 1-4. Go to original source...
  12. Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol. 1998; 139 (suppl 52): 41-47. Go to original source...
  13. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997; 36(Pt 2): S96-S103. Go to original source...
  14. Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol 1997; 36(Pt 2): S119-S125. Go to original source...
  15. Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul 1996; 13: 575-588. Go to original source... Go to PubMed...
  16. Leyden J, Lowe N, Kakita I, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001; 67(Suppl 6): 10-16. Go to PubMed...
  17. Meichenbaum D, Turk DC. Facilitating Treatment Adherence: A Practitioner's Guidebook. New York, NY: Plenum Press 1987: 11-75. Go to original source...
  18. Katsambas AD. Why and when the treatment of acne fails. What to do. Dermatology 1998; 196: 158-161. Go to original source... Go to PubMed...
  19. Bikowski J. The use of cleansers as therapeutic concomitants in various dermatologic disorders. Cutis 2001; 68 (Suppl 5): 12-19. Go to PubMed...
  20. Dunlap FE, Baker MD, Plott RT, et al. Adapalene 0.1% gel has low skin irritation potential even when applied immediately after washing. Br J Dermatol 1998; 139(Suppl 52): 23-25. Go to original source... Go to PubMed...
  21. Gollnick HPM, Rizova E, Kligman A, el at. Adapalene in the Treatment of Acne: 5-Year Worldwide Clinical Retrospective. J Eur Acad Dermatol Venereol 2001; (Suppl 3): 2-67.
  22. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 3(Suppl): 200-210. Go to original source... Go to PubMed...
  23. Cunliffe WJ, Forster RA, Greenwood ND et al. Tetracycline and acne vulgaris: a clinical and laboratory investigation. Br Med J 1973; 4: 332-335. Go to original source... Go to PubMed...
  24. Betolli V, Mantovani L, Borghi A, et al. Adapalene 0,1% cream after oral isotretinoin: Evaluation of the acne reccurence incidence (abstract). In: CD of abstracts, 15th Congress of the EADV, Greece, Rhodos, October 3-7, 2006.
  25. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene Gel, 0.1%, as Maintenance Therapy for Acne Vulgaris: A Randomized, Controlled, Investigator-Blind Follow-up of a Recent Combination Study. Arch Dermatol 2006; 142(5): 597-602. Go to original source... Go to PubMed...
  26. Zhang JZ, Li LF, Tu YT, et al. A successful maintenance approach in inflammatory acne with adapalene gel, 0.1% after an initial treatment with in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004; 15: 372-378. Go to original source... Go to PubMed...
  27. Alizerai M, George SA, Coutts I et al. Daily treatment with adapalene gel 0,1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007; 17: 45-51.
  28. Gollnick HPM, Cunliffe WJ. 2005 Global Alliance. A report from a Global alliance to improve outcomes in acne. Printed in USA by Galderma International 2006, May.
  29. Leyden JJ, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol 2006; 142: 605-612. Go to original source... Go to PubMed...
  30. Nevoralová Z. Sledování souboru pacientů s těžkými formami acne vulgaris léčených perorálním izotretinoinem. is. muni.cz/th/229525,lf-d/PhD_prace-Nevoralova_.pdf.
  31. Poulin Y, Sanchez NP, Bucko A, et al. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. British Journal of Dermatology 2011; 164: 1376-1382. doi: 10.1111/j.1365-2133.2011.10344.x Go to original source... Go to PubMed...
  32. Bettoli V, Borghi A, Zauli S, et al.Maintenance therapy for acne vulgaris: efficacy of a 12-month treatment with adapalene-benzoyl peroxide after oral isotretinoin and a review of the literature. Dermatology 2013; 227(2): 97-102. doi: 10.1159/000350820. Epub 2013 Sep 11. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.